Fierce Biotech News & Reports

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on Fierce Biotech as their must-read sour...

MYWOT

Child safety

Confidence

Trustworthiness

Confidence

MALICIOUS CONTENT INDICATORS

Fiercebiotech.com most likely does not offer any malicious content.

Secure connection support

HTTPS

Fiercebiotech.com provides SSL-encrypted connection.

ADULT CONTENT INDICATORS

Fiercebiotech.com most likely does not offer any adult content.

Audience

Bounce rate

The accuracy of the provided data is based on the latest estimates available to us and can significantly differ from the real-life website stats, so should be taken with caution.
Time on site

The accuracy of the provided data is based on the latest estimates available to us and can significantly differ from the real-life website stats, so should be taken with caution.

01:37

AVG
Gender

The accuracy of the provided data is based on the latest estimates available to us and can significantly differ from the real-life website stats, so should be taken with caution.

Men

35.5%

Women

69.5%

Popular pages

Fierce Biotech Homepage | Fierce Biotech
Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on Fierce Biotech as their must-read source for the latest news, analysis and data in the world of biotech and ...
Life Technologies and Sino Biological Inc. Sign Strategic Partnership Agreement for Global
Partnership Establishes Leadership Position in Proteomics Markets, China and Worldwide BEIJING, Aug.
Moon Surgical raises $55M, taps Fred Moll as board chair
With a fresh injection of venture funding and a high-profile addition to its board, Moon Surgical is entering a new phase.
FDA approves Abbott's spinal cord stimulators for back pain
Abbott is putting the old adage that “good things come in threes” to the test, with its fourth FDA approval in a year for its spinal cord stimulators.
Roche passes phase 2 multiple sclerosis trial with clean profile
Roche’s BTK inhibitor has hit the mark in a midphase MS trial—without causing adverse events that sparked holds on Merck KGaA and Sanofi’s rivals.
Takeda puts $510M on the line to expand KSQ cancer collaboration
Takeda is handing over “double-digit millions of dollars” on day one to research and validate novel tumor-intrinsic targets.